Tonix Pharmaceuticals reports Q2 net loss of $28.3 mln
Overview
Tonix Q2 reports net loss of $28.3 mln, compared to net loss of $78.8 million last year
Reports basic EPS of -$3.86
Company's cash position improves to $125.3 mln, funding operations into Q3 2026
Outlook
Tonix expects FDA decision on TNX-102 SL by August 15, 2025
Company anticipates cash runway to fund operations into Q3 2026
Tonix preparing for potential TNX-102 SL commercialization in Q4 2025
Result Drivers
TNX-102 SL - Phase 3 results show significant pain reduction in fibromyalgia patients, supporting NDA review
INCREASED EXPENSES - Higher SG&A expenses due to pre-launch activities for TNX-102 SL
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 Net Income |
| -$28.27 mln |
|
Q2 Basic EPS |
| -$3.86 | -$3.21 (2 Analysts) |
Q2 Operating Income |
| -$28.30 mln | -$26.30 mln (1 Analyst) |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for Tonix Pharmaceuticals Holding Corp is $65.00, about 28.5% above its August 8 closing price of $46.49
Press Release: ID:nGNX5gt8L1
